Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. McDermott on IMmotion150 Trial in RCC

February 22nd 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

First SITC Guidelines in RCC Address Continuing Role of Interleukin-2 and Emergence of Nivolumab

February 21st 2017

New guidelines involving the immunotherapies nivolumab (Opdivo) and interleukin-2 inhibitors have been issued by The Society for Immunotherapy of Cancer to help practicing clinicians manage patients with renal cell carcinoma.

Vogelzang Emphasizes Aggressive Biopsies, Novel Therapies in Urothelial Carcinoma

February 21st 2017

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.

Cabozantinib Regimens Active Across Multiple Advanced GU Malignancies

February 21st 2017

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

Combination Makes First-Line Case for Metastatic PD-L1+ RCC

February 21st 2017

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.

Dr. Powles on Durvalumab in Urothelial Cancer

February 20th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Checkpoint Inhibitors Continue to Offer New Hope in Urothelial Cancer

February 20th 2017

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

Pembrolizumab Plus Chemo Shows Promise in Urothelial Carcinoma

February 19th 2017

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC

February 18th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Dr. Steinberg on Trial of HS-410 Vaccine in Bladder Cancer

February 18th 2017

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).

Durvalumab Impresses in Advanced Urothelial Cancer

February 18th 2017

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer

February 18th 2017

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Dr. Apolo on Study of Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma

February 17th 2017

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCC

February 17th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

Phase III Results Support Novel Focal Therapy for Low-Risk Prostate Cancer

February 16th 2017

Padeliporfin vascular-targeted photodynamic therapy, a novel tissue-preserving treatment, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy, according to the results of a phase III trial.

Durable Responders Emerge Even After Stopping Their PD-1/PD-L1 Therapy for Kidney Cancer

February 14th 2017

Some patients who had to stop their PD-1/PD-L1 immunotherapy because of an immune-related adverse event proved to be sustained responders, even after being off the therapy for more than 6 months.

Intermittent Sunitinib Feasible in Metastatic Renal Cell Carcinoma

February 9th 2017

The findings from the phase II study of intermittent sunitinib in patients with previously untreated metastatic renal cell carcinoma demonstrate that periodic extended sunitinib treatment breaks are feasible and the clinical efficacy does not seem to be compromised.

Dr. Shuch on Biology of Non-Clear Cell RCC

February 9th 2017

Brian M. Shuch, MD, assistant professor of Urology and of Radiology and Biomedical Imaging, Yale Cancer Center, discusses the biology of non-clear cell renal cell carcinoma (RCC).

Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer

February 7th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.

Dr. Figlin on the Plethora of Novel Agents in RCC

February 7th 2017

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the major novel agents at the forefront of the treatment landscape of renal cell carcinoma.